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Introduction: Detection of anaplastic lymphoma kinase (ALK)-
gene rearrangements in non–small-cell lung cancer (NSCLC) is 
mainly performed by fluorescence in-situ hybridization (FISH). 
The question was raised if FISH might be replaced by immuno-
histochemistry (IHC) in a reliable and reproducible manner across 
different laboratories.
Methods: After calibration of the staining instruments and training 
of the observers to binary interpretation (positive versus negative), 15 
NSCLC were independently tested for ALK protein expression by IHC 
only in a multicenter setting (16 institutes). Each laboratory utilized the 
VENTANA ALK-D5F3 IHC assay. As demonstrated by FISH the sam-
ples displayed unequivocal ALK break-positivity (6×) and negativity 
(7×), as well as ALK positive-“borderline” character (2×), which is 
challenging for FISH diagnosis and thus was RT-PCR-confirmed.
Results: All seven ALK FISH-negative cases were homogenously 
scored as ALK-IHC negative. All 16 participants scored the two ALK 
positive-“borderline” samples as unequivocally positive accord-
ing to their protein expression. Concordant IHC interpretation was 
also noticed in four of six unequivocal ALK break positive cases. 
In two of six some observers described a weak/heterogeneous ALK-
IHC staining. This would have resulted in a subsequent ALK-testing 
(FISH/PCR) in a routine diagnostic setting.
Conclusions: This so-called “ALK-Harmonization-Study” shows 
for the first time that predictive semiquantitative IHC reveals reliable 
and reproducible results across several labs when methodology and 
interpretation are strictly defined and the pathologists are uniquely 
trained. The application of validated ALK IHC assays and its com-
parison to ALK-FISH is highly needed in future clinical trials. This 
might answer the question if ALK-IHC cannot only serve as a pre-
screening tool, but as a stand-alone test at least in cases displaying an 
unequivocally staining pattern as well as an alternative predictive test 
in samples with reduced FISH interpretability.
Key Words: Non–small-cell lung cancer, Anaplastic lymphoma 
kinase gene rearrangement, Immunohistochemistry, Harmonization, 
Multicenter-validation.
(J Thorac Oncol. 2014;9: 1685–1692)
Rearrangements in the anaplastic lymphoma kinase (ALK) gene are detectable in approximately 2 to 7%1,2 of non–
small-cell lung cancers (NSCLC). A paracentric inversion 
within the ALK-gene of chromosome 2 leads to a fusion with 
the EML4-gene or rarely with other partners (translocation: 
KIF5B, TFG, and KLC1)1–3 and results in an expression of the 
oncogenic ALK-protein, providing a target for ALK-tyrosine 
kinase inhibitors (TKI).4–6 ALK rearrangements mostly occur in 
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KRAS and EGFR wild type adenocarcinomas and preferentially 
arise in young and nonsmoking patients.7–9 As the identification 
of ALK activity is crucial for the prescription of ALK-TKIs, 
a reliable diagnostic detection is of utmost importance. The 
studies leading to the approval of this therapeutic regimen were 
based on fluorescence in-situ hybridization (FISH), the current 
diagnostic gold standard.2,4–6 However, FISH is expensive, time-
consuming, and requires special equipment. Still, the detection 
of ALK rearrangements may not only fail due to technical (e.g., 
auto-fluorescence, overdigestion) and material-based reasons 
(e.g., low number of tumor cells), but also can be complex 
and challenging, as the most common alteration, the intra-
chromosomal inversion, may lead to subtle separations of the 
5′and 3′signals. This has led to false-positive and false-negative 
interpretations.10–15 As recent studies based on immunohisto-
chemistry (IHC) showed promising results, the detection of the 
ALK protein was suggested as a further diagnostic option.15–21 
However, to perform ALK testing with robust reproducibility 
and reliability across different laboratories a careful validation 
is required. This necessity was addressed in the here presented 
“ALK-Harmonization-Study”: after harmonization of the tech-
nical procedure and webinar-based ALK-IHC interpretation 
training of all observers (16 institutes of pathology), the partici-
pants had to perform ALK-testing (negative versus positive) of 
15 well-characterized NSCLC samples by IHC only.
MATERIAL AND METHODS
Tumor Sample Selection and Pretesting by FISH
Fifteen well-characterized NSCLC samples (12× ade-
nocarcinoma, 1× adenosquamous carcinoma, 1× squamous 
cell carcinoma, and 1× cell line [H2228]; Table 1) had been 
selected out of a previously described cohort (retrospective) of 
lung cancer tissues.12 FISH pretesting was performed on whole 
slide tissue sections. Four-micrometer thick sections were cut, 
mounted on SuperFrost +/+ slides, and deparaffinized. A com-
mercially available break-apart dual color probe for the ALK 
gene (Vysis LSI ALK Dual Color; Abbott Molecular, Abbott 
Park, IL) was used in accordance to the manufacturer’s instruc-
tions. The 5′ALK probe was labeled with SpectrumGreen and 
the 3′ALK probe with SpectrumOrange. One hundred non-
overlapping cells with hybridization signals were examined 
for each case with a fluorescence microscope (Axio Imager 
Z1, Zeiss, Jena, Germany) at a 63× oil immersion objective. 
ALK-FISH was considered positive if at least 15% of 100 ana-
lyzed tumor cells showed splitting of the fluorescent probes 
flanking the ALK-gene or loss of the 5′ signal, as described 
elsewhere.2,7,12,15–17,19,22 Seven samples were unequivocally ALK 
break-negative and displayed a maximum of 3% split signals 
(SS). One of these seven samples (a squamous cell carcinoma) 
was included because of its unusual; however, ALK-break 
negative FISH pattern with single green signals in approxi-
mately 70% of the tumor cells. Six samples were unequivo-
cally ALK break-positive and displayed SS and/or single red 
signals (SRS) in at least 40% of the tumor cells (mainly one 
alteration per nucleus). One of these six samples was currently 
reported as “new” EML4-ALK variant23 that displays a fusion 
of Exon 6 (EML4) and Exon 19 (ALK). The remaining two 
cases were classified as ALK positive-“borderline” NSCLC, as 
showing a low percentage of ALK break-positive cells (around 
the cut-off of 15%) by FISH analysis. Both had been confirmed 
as EML4-ALK variant 1 and 3a/b by RT-PCR and subsequent 
sequencing of the breakpoints (no therapy response data were 
available in these samples).
Tissue Microarray (TMA) Construction 
and Retesting at Leading Sites
Two TMAs consisting of the above-described 15 NSCLC 
samples were constructed (three cores for each case, 1-mm 
diameter per core, resulting in a total of 45 cores). TMA-1 
TAbLE 1.  Fifteen NSCLC Samples and Their ALK Status (Positive or Negative) by Means of IHC and FISH as Well as Their 
RT-PCR Products (Variants 1, 2, 3a/b, Atypical Variant, 3′ALK-Transcript)
Case ALK-IHC ALK-FISH RT-PCR Comment
1 Pos. SS, SRS (~69%) Variant 3a/b
2 Neg. Neg. (<3%) Neg.
3 Pos. Atypical SS/SRS (~80%) 3′ALK-transcript “Mickey-mouse” “Loss of red” (not a Variant 1,2,3)
4 Neg. Neg. (<3%) Neg. Pitfall in IHC (macrophages)
5 Neg. Neg. (<3%) Neg.
6 Pos. SS, SRS (~15–20%) Variant 1 “Borderline case”; ADC+SCC
7 Neg. Neg. (<3%) Neg.
8 Pos. SRS (~80%) 3′ALK-transcript Not a Variant 1,2,3
9 Neg. Neg. (<3%) Neg. Pitfall in IHC (necrosis); SGS in FISH; SCC
10 Pos. SS, SRS (~15%) Variant 3a/b “Borderline case”
11 Pos. SS, SRS (~40%) Variant 1
12 Neg. Neg. (<3%) Neg.
13 Neg. Neg. (<3%) Neg.
14 Pos. Mainly SS (~74%) Exon 6 (EML4) to Exon 19 (ALK) New Variant23
15 Pos. Mainly SRS (~70%) Variant 3a/b CL-H2228
FISH, fluorescence in-situ hybridization; IHC, immunohistochemistry; Pos., positive; Neg., negative; SRS, single red signal; SS, split signal; SGS, single green signal; ADC, 
adenocarcinoma; SCC, squamous cell carcinoma; CL, cell line.
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obtained eight cases (24 cores), TMA-2 the other seven cases 
(21 cores). Two landmark cores (palatine tonsils) serving as 
orientation and as a negative control were placed in the right 
upper corner of each TMA. Each TMA was cut in 43 serial 
sections, each of 3- to 4-μm thickness. TMA-based ALK-FISH 
was performed at Berlin (sections 1, 22, and 42) and Heidelberg 
(sections 2, 24, and 43). This re-evaluation confirmed the 
above-described ALK-status (on whole slide tissue section) in 
the first, middle, and last sections of the TMAs (Fig. 1).
Harmonization of the Staining 
Instruments and Observer Training
Before the multicenter TMA-based case testing, each 
staining instrument (14× VENTANA BenchMark XT, 2× 
BenchMark GX [Tucson, AZ]) was calibrated and quali-
fied using the VENTANA ALK 2 in 1 Control Slides. Each 
participant performed at least four control runs with accept-
able staining patterns according to the VENTANA ALK-
Interpretation-Guide.25 To provide a uniform baseline 
interpretation, a webinar-based training was given to all 
observers. This training included a virtual meeting to review 
the VENTANA ALK-Interpretation-Guide and two Training 
Sets of ten virtual scanned (VENTANA Image Viewer) cases 
(H&E and IHC). Subsequently each participant had to per-
form a review of another 50 patient cases (H&E and IHC, all 
FISH-confirmed), as described elsewhere.24 All participants 
passed this ALK-proficiency exam as they performed ALK 
classifications correctly in at least 45 cases (90%).
Panel-Test Workflow
TMA slides 5, 23, and 39 were H&E-stained and made 
available electronically as digital slides (Nanozoomer 2.0; 
Hamamatsu) for reviewing by all participating institutes 
(Fig. 1). Evaluation included the determination of acceptability 
of every single core concerning the amount of tumor cells. A 
mean of 43.3 of 45 H&E cores (96.3%; ratio: 42–45 cores) 
was accepted by the participants and demonstrated the qual-
ity of the TMAs at the different levels. The other slides were 
shipped to the participating institutes of pathology (Belgium, 
Denmark, France, Germany, Scotland, Spain, Sweden, and 
Switzerland) within 7 days after sectioning. Each participant 
received four slides (two per TMA). After each institute had 
performed the single IHC-staining steps (for staining proce-
dure see below), every observer evaluated the tissue quality 
(sufficient tumor tissue, extent of necrosis) of the four obtained 
TMA slides. A total of 703 of 720 cores (97.6%) were scored 
suitable (ratio: 42–45 cores per participant). Thus, at least two 
out of three cores per case could be scored.
Each observer performed independent testing with-
out knowledge of the FISH results. The overall ALK-IHC 
status of every case had to be reported as negative or posi-
tive (binary interpretation) using the ALK (D5F3) Rabbit 
Monoclonal Primary Antibody combined with the OptiView 
DAB IHC detection and the OptiView Amplification kits (all 
VENTANA). The ALK status was called positive if tumor 
cells in at least one of the three cores of a case showed a 
strong cytoplasmic staining pattern.25 A case was called ALK 
negative if all three cores showed no adequate staining pattern 
according to the ALK Interpretation Guide.25
All results including the stained TMAs were sent to 
the Institute of Pathology Charité, Berlin for comparison 
and data collection. All slides were scanned (Nanozoomer 
2.0; Hamamatsu, Hamamatsu City, Japan) and included in a 
PDF forming the basis for a consecutive telephone confer-
ence (Supplemental Digital Content, http://links.lww.com/
JTO/A689).
As the overall concordance of the results was high, a 
special focus was set on case 8 and 11 which was not called 
clearly ALK-IHC positive by a total of five observers. A 
FISH B
FISH HD
participant 1
HE electronical for all participants
slides 1-43
HE electronical for all participants
FISH HD
FISH B
participant 16 
HE electronical for all participants
1 2 3 4 5 
16 slides (6-21) for 
7 participants,
each 2 slides 
39 22 23 24 
14 slides 25-38 for 
7 participants,
each 2 slides 
40 41 42 43 
FISH B FISH HD
FIguRE 1.  Preparation and testing modality of the tissue microarrays (TMA): each of the two TMAs was cut into 43 slides. 
Slides 1, 2, 22, 24, 42, and 43 were tested by means of ALK-FISH in Berlin (B) and Heidelberg (HD). Slides 5, 23, and 39 were 
stained by H&E and were electronically available as scans.
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strong variance was seen within two observers (institutes 5 
and 8). Therefore the following question rose: Is the ALK-
IHC-staining intensity dependent of the time interval between 
TMA-cutting and staining?
To address this issue the following steps were conducted:
1.  Institutes 5 and 8 performed a restaining of further 
TMA sections.
2.  All staining results were correlated with the exact time 
interval (days from cutting to staining).
3.  An additional TMA staining was performed after 128 
days of being cut (at Berlin, Charité).
ALK-D5F3 IHC
The VENTANA anti-ALK (D5F3) Rabbit Monoclonal 
Primary Antibody has been developed for use on VENTANA 
BenchMark XT and BenchMark GX automated slide stainers 
in combination with Rabbit Monoclonal Negative Control Ig, 
OptiView DAB IHC detection and OptiView Amplification 
kits. All 16 laboratories performed the staining procedure 
according to the manufacturer’s instructions and as described 
elsewhere.26 As an additional component, staining of the 2 in 1 
control slide was performed at each procedure. This slide con-
tains two human cell lines (ALK-positive and ALK-negative) 
serving as controls for the staining quality. An adequate stain-
ing procedure with the D5F3-clone can be assumed when one 
cell line is strongly positive and the other negative.
For adequate interpretation a special step-by-step pro-
cedure was recommended: (1) the observers had to review the 
virtual H&E slides, to determine the amount of tumor cells 
and the number of adequate cores per case (x/3). (2) The ade-
quacy of the staining procedure had to be evaluated by inter-
preting the 2 in 1 control slides. (3) The staining quality and 
intensity of the Negative Control Slide and the ALK-D5F3 
tissue slide had to be compared to determine false positive 
(e.g., macrophages, nerve fibers, and necrosis) and specific 
tumor staining patterns (strong cytoplasmic).
RESuLTS
binary ALK-IHC Evaluation of 
15 NSCLC Samples
Despite some artifacts as staining of macrophages, nerve 
fibers, and stroma components all 16 participants designated 
all seven ALK-FISH-negative cases as ALK-IHC-negative 
(Table 2, Fig. 2). All observers scored the two ALK-FISH pos-
itive-“borderline” cases (RT-PCR: EML4-ALK variant 1 and 
3a/b) as positive according to their ALK expression profile. This 
concordant IHC interpretation was also noticed in four of the 
six unequivocally ALK-FISH positive samples. In the remaining 
two cases (number 8 and 11), a weak and heterogeneous staining 
was described by five observers. All of them performed staining 
on the BenchMark XT platform (Tables 2 and 3). This equivo-
cal pattern would have resulted in a subsequent testing by FISH 
(and/or PCR) under diagnostic conditions (Table 3, Fig. 2).
In detail, one participant called case 8 ALK nega-
tive, according to the strict rules of the ALK Interpretation 
Guide,25 as a strong cytoplasmic staining pattern was missing. 
However, the observer stated the occurrence of a weak and 
heterogeneous staining pattern, which would have resulted in 
additional ALK-FISH-testing in daily routine practice. The 
same was true for case 11. Four participants scored this case 
negative according to the ALK Interpretation Guide.25 Still, 
all of them described a heterogeneous, focally weak and “stip-
pled” staining pattern and would have demanded (as well as 
three other participants) for an additional independent ALK-
test (FISH and/or PCR).
TAbLE 2.  IHC Testing of Seven ALK-Negative Samples by 16 Institutes
Participant (BM) Case 2 Case 4 Case 5 Case 7 Case 9 Case 12 Case 13
1 (XT)
2 (XT)
3 (GX)
4 (XT)
5 (XT)
6 (XT)
7 (XT)
8 (XT)
9 (XT)
10 (XT)
11 (XT)
12 (XT)
13 (GX)
14 (XT)
15 (XT)
16 (XT)
Positive ALK-status in yellow.
BM, BenchMark GX or XT.
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Comparison of the Staining Intensities 
of all Panellists and Restaining
The comparison of the staining intensities showed minor 
differences between the majority of observers. However, 
major differences between two observers (institutes 5 and 8) 
especially in case 8 and 11 (Table 3). IHC staining by all par-
ticipants was performed between days 5 and 38 after TMA cut-
ting. The weak staining of institutes 5 and 8 referred to days 
23 and 36. Nevertheless a very strong cytoplasmic staining 
pattern was seen for example at days 24 and 38 in other insti-
tutes (see Supplemental Digital Content, http://links.lww.com/
JTO/A689). The restaining of institutes 5 and 8 showed much 
stronger staining patterns compared to their first run and was in 
line with the staining intensities of the other participants. The 
IHC run performed after 128 days showed strongly reduced 
IHC intensity: two of eight ALK-positive cases could not be 
detected as unequivocally positive any more (Supplemental 
Digital Content, http://links.lww.com/JTO/A689).
16/16 positive
case 1
16/16 positive
case 3 case 6 case 8 case 10
15/16 positive 16/16 positive16/16 positive
case 11 case 14 case 15 
12/16 positive 16/16 positive 16/16 positive
case 9 case 4 
16/16 negative16/16 negative
FIguRE 2.  Ten NSCLC cases stained with 
H&E, ALK-IHC (10× objective), and FISH (63× 
objective). Two ALK-negative cases with chal-
lenging IHC due to positivity of macrophages 
and necrosis are shown in cases 4 and 9. The 
latter displays a single green signal pattern 
(SGS) in FISH. At the bottom the interpreta-
tion of all 16 observers (negative versus posi-
tive) is given. Note the heterogeneous staining 
pattern in case 11.
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DISCuSSION
The main methods of ALK testing are IHC and FISH. 
The latter is a validated FDA approved test (companion diag-
nostic). However, FISH has some technical and interpreta-
tional disadvantages. Furthermore, as approximately 80 to 
90%27–29 of lung cancer diagnosis is based on small biopsies, 
the amount of tumor cells can be too low to perform a depend-
able ALK-FISH diagnosis. Therefore, to improve the quality 
of ALK testing, several studies compared IHC and FISH with 
encouraging results. However, due to the occurrence of ALK 
IHC-positive/FISH-negative samples (and vice versa!), these 
studies had not been sufficient to establish IHC as the stand-
alone diagnostic approach.15–21 Furthermore, it must be noted 
that a majority of the cited investigations was validated and 
performed within single laboratories, whereas multicenter use 
of ALK-IHC showed heterogeneous results according to dif-
ferent antibodies, dilutions, detection, and amplification sys-
tems obtained.12
In this study, we investigated and proved the multicenter 
reliability of an IHC-based ALK testing. The basis for mul-
ticenter applicability was the harmonization of the staining 
protocol within the staining instruments, a preceding valida-
tion procedure of each instrument and a webinar-based teach-
ing of all participants. Teaching is highly recommended24 as 
the described ALK-detection-approach might cause positivity 
not only in tumor cells, but also in other tissue components 
such as macrophages, nerve fibers, and areas of necrosis (see 
cases 4 and 9, Fig. 2B). Homogeneous (ALK-protein nega-
tive) results were shown in all seven NSCLC-samples without 
ALK rearrangement. The same was true for six of eight ALK-
rearranged samples. Thereby, it is of special interest that all 16 
participants scored both ALK-“borderline” samples positive 
according to their ALK protein expression. ALK-testing of 
these “borderline” samples by 16 different observers based on 
FISH only would have led to very deviating ALK-status inter-
pretations (misinterpretations!). However, both samples were 
RT-PCR confirmed EML4-ALK variants and are treatable tar-
gets that are mandatory to detect! One of the two was part of 
a recent retrospective study,12 where we could show that three 
of eight experienced observers did not evaluate this sample 
as ALK-positive due to technical limitations of the FISH-
approach, especially in samples harboring subtle SS pat-
terns.12,13 The here described two “borderline” samples might 
quasi represent these kind of NSCLC reported elsewhere as 
IHC positive and FISH negative, but sensitive to an ALK-
TKI.19,20,30 As the reduction of tumor volume and the response 
to ALK-inhibitors in ALK-positive-NSCLC was shown to be 
independent of the amount of ALK-positive tumor cells,31 the 
detection of cases with subtle splits (around the cut-off of 
15%) is of high importance. Therefore, in these samples a pre-
dictive ALK-interpretation cannot be based upon FISH only.
In two unequivocally ALK-break positive samples a few 
observers described a weaker and heterogeneous “stippled” 
IHC-staining pattern (Table 3). Even though the participants 
felt to interpret this equivocal ALK pattern as negative due to 
the strict rules of the ALK Interpretation Guide,25 all wished 
to perform an add-on FISH and/or PCR test. Interestingly all 
observers reporting an equivocal result performed staining on 
the BenchMark XT platform, whereas the two investigators 
referring to the GX did not describe these kind of weak expres-
sion patterns. Regardless, this phenomenon was found in two 
cases only. Furthermore, all remaining participants using the 
XT did not report questionable IHC patterns (Table 3). Thus, 
this effect is unlikely a matter of platform, but should be more 
likely discussed as being due to tumor heterogeneity or (even 
more plausible) as related to tissue damage of the TMA spots 
TAbLE 3.  IHC-Testing of Eight ALK-Positive Samples by 16 Institutes
Participant (BM) Case 1 Case 3 Case 6 (BL*) Case 8 Case 10 (BL*) Case 11 Case 14 Case 15
1 (XT) FISH FISH
2 (XT)
3 (GX)
4 (XT)
5 (XT) FISH**
6 (XT) FISH/PCR
7 (XT)
8 (XT) FISH**
9 (XT) FISH**
10 (XT)
11 (XT)
12 (XT) FISH**
13 (GX)
14 (XT)
15 (XT) FISH**
16 (XT) FISH
Both ALK-FISH-“borderline” cases (=*BL) had been detected by all participants, in case 8, one observer and in case 11, four observers called staining as equivocal/low level 
staining/questionable negative and of uncertain significance (**). They stated that they would have tested with add on ALK-FISH. In these two cases, another three observers would 
have tested with add on FISH and/or PCR despite of their positive IHC-result (negative ALK-status in red, positive ALK-status in yellow).
BM, BenchMark GX or XT.
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and technical (platform independent) issues. The latter argu-
ment is underlined by the fact that restaining showed stron-
ger staining patterns compared to their first run and was in 
line with the staining intensities of the other participants. 
Regardless, our results showed that slight differences in the 
intensities of staining might occur even if all efforts for har-
monization of all components are done (Supplemental Digital 
Content, http://links.lww.com/JTO/A689). The latter might be 
due to local laboratory reasons (e.g., air pressure, temperature, 
and water quality) and seems to be independent of the time 
interval between cutting and staining (if performed within the 
first 38 days). Staining results after 128 days showed that IHC 
intensity was strongly reduced and that two of eight ALK-
positive cases could not be detected as unequivocally posi-
tive any more (Supplemental Digital Content, http://links.lww.
com/JTO/A689).
One major issue of future ALK interpretation will be to 
identify the frequency of samples with a deviating IHC/FISH 
ALK-status. As discussed above IHC-positive/FISH negative 
samples that are sensitive30 to ALK-inhibitor therapy might be 
“borderline” cases with very subtle ALK-breaks that might 
not be detected adequately by FISH.19 Thus, in these cases a 
validated ALK-IHC assay might serve as a stand-alone test 
if the staining pattern is unequivocal. However, this needs 
to be proven in future clinical trials. On the other hand, the 
rather rudimentary knowledge of IHC-negative/FISH-positive 
NSCLC needs further investigation as well19:
•  Is it a technical reason with false negativity of IHC or 
false positivity of FISH?
•  Is it biology with a genomic alteration within the ALK-
gene that does not lead to a cytoplasmic accumulation of 
the ALK-protein?
•  Do these samples show a specific FISH pattern (e.g., 
single red signals only)?
•  What about the therapy response data?
Future studies combining these molecular and clini-
cal key questions of ALK discrepancy could help to imple-
ment reliable test algorithms. These could be mainly based on 
the detection of the ALK protein (prescreening) with FISH 
being required only if IHC is in doubt (Fig. 3). This would not 
only clarify and specify ALK reporting but also could help to 
save time, money, and tissue for additional molecular tests. 
Furthermore, it would identify exactly those patients who ben-
efit of the TKI. Meanwhile the presented ALK-IHC approach 
seems to be an alternative predictive option in samples with 
reduced FISH interpretability (e.g., minimal tumor content in 
small biopsies, decalcified or altered tissue, and subtle splits).
To conclude, after harmonization of the staining instru-
ments and training of the observers, the ALK-D5F3 IHC 
A Possible NSCLC-ALK-Status-Algorithm
NSCLC
always ALK-IHC up front testing
for: ADC, LC, AD-SCC, NOS
(SCC only if requested)
ALK-IHC negative ALK-IHC equivocal(„stippled pattern“)
ALK-IHC unequivocal
(„strong cytoplasmic“)
possibly no ALK-FISH in future
currently need for
ALK-FISH to figure out 
the possible incidence of 
IHC-/FISH+ samples
(investigatory reasons)
add on ALK-FISH needed to 
report the definitive 
ALK-status
(FISH-based diagnosis)
Currently
add on ALK-FISH to confirm
the ALK-status (FDA-based)
possibly no ALK-FISH needed
in future (EMA-based)
FIguRE 3.  ALK-IHC-testing-proposal: a reliable IHC approach needs to be embedded in upcoming algorithms of NSCLC 
ALK-status testing. ALK-IHC may deliver three results: (a) ALK-IHC negative: in future, no additional ALK-FISH testing may be 
required (EMA-based concept). Therefore, upcoming clinical trials need to evaluate incidence and therapy-response data in 
patients with IHC-/FISH+ tumors. At the moment ALK-FISH should be performed if TKI-therapy is an option (FDA-based con-
cept). (b) ALK-IHC equivocal (“stippled” staining pattern): at the moment and in future add-on ALK-FISH should be performed 
to define the final ALK-status. Therapy decision is based upon FISH (FDA-based concept). (c) ALK-IHC unequivocal (positive): in 
future, no additional ALK-FISH testing may be required (EMA-based concept). Therefore, upcoming clinical trials need to evalu-
ate incidence and therapy-response data in patients with IHC+/FISH- tumors. It will be of highest interest if those samples show 
false negativity in FISH due to technical reasons and if the fusion transcript can be detected by PCR. At the moment ALK-FISH 
should be performed even if ALK-IHC is unequivocally positive (FDA-based concept).
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assay in combination with OptiView DAB IHC detection 
and OptiView Amplification kits can be regarded as a reli-
able multicenter technique for the detection of ALK protein 
expression. However, there is need to compare validated ALK 
IHC assays and ALK-FISH in future clinical trials. Therapy 
response data of patients with deviating ALK status by means 
of IHC and FISH will help to implement ALK-IHC not only 
as a prescreening tool, but also as a potential stand-alone test 
(at least in cases displaying an unequivocally staining pattern) 
and as the dependable alternative predictive test in samples 
with reduced FISH interpretability. Until then, as FISH has 
some disadvantages and even validated IHC may produce 
equivocal staining patterns, currently ALK diagnosis should 
be based on the rational application of both methods (Fig. 3) 
adapted to the given case.
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